2016

Variation in practice regarding pretreatment with dual antiplatelet therapy for patients with non–ST elevation myocardial infarction

Ali Shafiq
University of Missouri-Kansas City

Javier Valle
University of Colorado

Jae-Sik Jang
Inje University

Mohammed Qintar
University of Missouri-Kansas City

Kensey Gosch
Saint Luke's Mid America Heart Institute

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Shafiq, Ali; Valle, Javier; Jang, Jae-Sik; Qintar, Mohammed; Gosch, Kensey; Cohen, David J.; Singh, Mandeep; Bach, Richard; and Spertus, John A., "Variation in practice regarding pretreatment with dual antiplatelet therapy for patients with non–ST elevation myocardial infarction." Journal of the American Heart Association. 5,6. e003576. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5380

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Ali Shafiq, Javier Valle, Jae-Sik Jang, Mohammed Qintar, Kensey Gosch, David J. Cohen, Mandeep Singh, Richard Bach, and John A. Spertus
Variation in Practice Regarding Pretreatment With Dual Antiplatelet Therapy for Patients With Non–ST Elevation Myocardial Infarction

Ali Shafiq, MD, MSc; Javier Valle, MD; Jae-Sik Jang, MD; Mohammed Qintar, MD; Kensey Gosch, MS; David J. Cohen, MD, MSc; Mandeep Singh, MD, MPH; Richard Bach, MD; John A. Spertus, MD, MPH

Background—Despite guideline recommendations, a significant number of patients with non–ST elevation myocardial infarction (NSTEMI) do not receive dual antiplatelet therapy (DAPT) before angiography “pretreatment.” While there may be valid clinical reasons to not pretreat, such as concern for bleeding or multivessel disease warranting coronary artery bypass graft surgery, the degree of variability and factors associated with DAPT pretreatment are unknown.

Methods and Results—From the multicenter TRIUMPH registry, 1632 NSTEMI patients were not taking DAPT on admission and were included in the study cohort. Among the study patients, only 22% patients received DAPT pretreatment. A multivariable logistic regression model showed that race other than white or black (odds ratio [OR] 0.41, 95% CI 0.21–0.83), hemoglobin level (OR 1.18, 95% CI 1.08–1.29), patients’ bleeding risk (assessed with NCDR CathPCI Bleeding Risk Score) (OR 0.85, 95% CI 0.74–0.99), and severe left ventricular dysfunction (OR 0.3, 95% CI 0.13–0.65) were the main predictors of pretreatment with DAPT, whereas likelihood of needing coronary artery bypass graft surgery (GRACE prediction model) was not (OR 1.09, 95% CI 0.88–1.35). Median ORs were calculated to assess variability of receiving DAPT pretreatment across sites after adjustment for patient characteristics. Receiving DAPT pretreatment varied substantially across sites (range 0–100%, mean OR 3.94, P<0.0001).

Conclusions—While deviating from guideline-recommended DAPT pretreatment in patients with NSTEMI was associated with patient factors (eg, bleeding risk), marked variation was present across sites after accounting for patient-level characteristics. This suggests that site-level interventions are needed to improve concordance with current guidelines. (J Am Heart Assoc. 2016;5:e003576 doi: 10.1161/JAHA.116.003576)

Key Words: dual antiplatelet therapy • non–ST-elevation myocardial infarction • variation in care

Although early administration of dual antiplatelet therapy (DAPT) with aspirin and a platelet adenosine diphosphate receptor (P2Y-12) inhibitor is recommended by current American Heart Association/American College of Cardiology guidelines,1 recent data have demonstrated that up to half of patients presenting with non–ST-elevation myocardial infarction (NSTEMI) do not receive DAPT before coronary angiography (“pretreatment”).2,3 Defining whether the variation in DAPT pretreatment is attributable to patient- or provider-level factors can identify the importance and strategy for quality improvement.

Many clinical considerations might support not using DAPT pretreatment, such as concerns for increased bleeding risk (eg, patients with low baseline hemoglobin, with low platelet counts, or taking long-term anticoagulants) or the expectation that the patients with NSTEMI might have underlying severe coronary vessel disease requiring coronary artery bypass graft surgery (CABG).4–9 Prediction models to detect the risk of bleeding after percutaneous coronary intervention (PCI), as well as to estimate the probability of undergoing CABG after a NSTEMI,10–13 have been developed to support such decisions, but whether avoiding DAPT pretreatment is associated with patient-centered risks is unknown. Moreover, the variability across hospitals in DAPT pretreatment for patients with NSTEMI, after accounting for patient-level considerations in its use can identify an important opportunity to increase the consistency of guideline concordant care across centers.

We used the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients’
Dual Antiplatelet Therapy Pretreatment Variation

Shafiq et al

Health Status (TRIUMPH) registry of patients with acute myocardial infarction (AMI) to examine practice pattern variations of DAPT pretreatment in NSTEMI patients. To illuminate patient-centered reasons for not using DAPT pretreatment, we examined the association of patient-level factors, including the recently validated Global Risk of Acute Coronary Events (GRACE) model and the National Cardiovascular Data Registry (NCDR) CathPCI Bleeding Risk Score, with the use of DAPT before PCI. After adjusting for these patient-level factors, we then examined site-level variations in DAPT pretreatment.

Methods

Study Design

The study was designed as a retrospective analysis of patients enrolled in the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients’ Health Status (TRIUMPH) registry. Details regarding the TRIUMPH registry have been described previously. In brief, TRIUMPH is a large prospective multicenter registry that successively enrolled patients across 24 sites with a diagnosis of AMI from April 2005 through December 2008, a time when there was broad consensus about the importance of DAPT pretreatment. Patients 18 years and older who had elevated cardiac enzymes (creatine kinase-MB or troponin-I) on hospital admission and characteristics of ischemia (chest pain or electrocardiographic (ECG) abnormalities consistent with a diagnosis of AMI) were eligible. Incarcerated patients were not eligible; patients were also excluded if they refused to participate in the registry, were unable to undergo informed consent, had prolonged transfer periods from nonparticipating facilities (>24 hours), or did not speak either English or Spanish. Trained study coordinators abstracted data from the medical records and performed baseline interviews within 24 to 72 hours of presentation to assess patients’ demographic, clinical, socioeconomic, health, and psychological status. At each participating site, institutional review boards approved the study protocol and each patient provided signed informed consent.

Analytic Cohort

Given the focus of the guidelines on patients with NSTEMI, we excluded patients with ST-elevation MI (STEMI) and those who were already taking DAPT as outpatients before admission. At the time of this study, DAPT consisted of aspirin and a P2Y-12 inhibitor (ie, clopidogrel or ticlopidine). We also excluded patients enrolled at 2 sites in the TRIUMPH registry that did not offer on-site CABG, where delays in CABG might be more common and concerns about more extensive coronary disease might be less relevant. The study cohort was then assessed to determine which patients received pretreatment with DAPT.

Statistical Analysis

Baseline characteristics of NSTEMI patients who did and did not receive DAPT pretreatment were compared by using Student t test for continuous variables and χ² tests for categorical variables (Table). Based on literature review and clinical criteria, we attempted to capture all patient and clinical characteristics that we thought might be associated with DAPT pretreatment. For example, we have previously validated the GRACE model as the best method for identifying the risk of patients for needing CABG in the setting of NSTEMI. Thus, to best capture this important reason for not pretreating with DAPT before angiography, we calculated the risk score by using the GRACE model for each patient on the basis of their sex; history of CABG, angina, congestive heart failure, dyslipidemia, hypertension, atrial fibrillation, and diabetes; and ECG findings. To assess whether the patients’ risk of bleeding was associated with avoiding DAPT pretreatment, we collected data regarding patients taking coumadin or any other oral anticoagulants on admission and their preprocedural platelet counts. We also calculated each patient’s NCDR CathPCI Bleeding Risk Score. Finally, we collected some additional variables based on clinical judgment that we thought might be associated with DAPT pretreatment; such as race, history of smoking, stroke/transient ischemic attack, peripheral arterial disease, chronic lung disease, family history of coronary artery disease, and baseline left ventricular (LV) function.

We then used hierarchical logistic regression models, with site-centered covariates, to assess whether our collected variables had a significant association with DAPT pretreatment. The raw rates of DAPT pretreatment were assessed among all study sites. To assess the extent of variability in DAPT pretreatment across sites, we calculated the median odds ratios (MOR). The MOR estimates the difference in likelihood of receiving DAPT pretreatment at one random study site versus the other after accounting for patient-level characteristics. SAS version 9.4 was used to perform all analyses. All analyses were prespecified, and a 2-sided P value <0.05 denoted statistical significance.

A majority of patients (93%) were not missing any covariate information, with 2% missing 1 value and 5% missing ≥2. The highest missing rate for any single variable was 4.8% (GRACE CABG Risk Score), followed by smoking status, which was missing in 0.6% of patients. To correct for any biases because of the small number of missing covariates, data were imputed by using an imputation model that contained all of the variables from the multivariable model. Data were imputed using an imputation model that contained all of the variables from the multivariable model. Table S1 shows no significant differences
when comparing the output of logistic regression models with and without missing data.

Results

Study Population

There were 4340 patients with an AMI enrolled in the TRIUMPH registry. We excluded patients with STEMI (n=1860), those who were already taking DAPT on admission (n=387), and patients who did not have information regarding their pretreatment with DAPT (n=390). We further excluded 71 patients who were enrolled at 2 sites in the TRIUMPH registry that did not perform on-site CABG. The final study cohort consisted of 1632 NSTEMI patients across 22 study sites (Figure 1).

Unadjusted Association of Patient Factors With DAPT Pretreatment

Among the study cohort, 359 (22%) patients received pretreatment with DAPT. Table shows the overall demographic and clinical characteristics of patients who did and did not receive pretreatment with DAPT. Patients in the pretreatment group were younger and more likely to be male and white, with a lower prevalence of prior CABG, MI, heart failure, hypertension, and diabetes. The pretreatment group was also more likely to have a higher hemoglobin level, to not be taking warfarin, and to have normal LV systolic function. Paradoxically, the likelihood of having multivessel coronary disease

### Table. Baseline Characteristics of NSTEMI Patients Undergoing DAPT Pretreatment Versus No Pretreatment

| Variable                          | DAPT Pretreatment, n=359 | No Pretreatment, n=1273 | P Value |
|-----------------------------------|--------------------------|-------------------------|---------|
| Mean age, y                       | 58.3±12.4                | 60.5±12.7               | 0.003   |
| Male                              | 69.6%                    | 62.7%                   | 0.015   |
| Race                              |                          |                         | <0.001  |
| White/Caucasian                   | 72.8%                    | 58.8%                   |         |
| Black/African American            | 22.8%                    | 35.6%                   |         |
| Other                             | 4.5%                     | 5.7%                    |         |
| Smoking status (<30 d)            | 37.3%                    | 35.4%                   | 0.669   |
| Former (<30 d)                    | 32.6%                    | 32.1%                   |         |
| Never (<100 d)                    | 30.1%                    | 32.5%                   |         |
| Medical history                   |                          |                         |         |
| Prior angina                      | 12.0%                    | 13.1%                   | 0.569   |
| Prior CABG                        | 6.4%                     | 12.6%                   | 0.001   |
| Prior MI                          | 15.9%                    | 22.7%                   | 0.005   |
| Prior PCI                         | 16.7%                    | 14.8%                   | 0.385   |
| Prior CVA or TIA                  | 5.0%                     | 8.3%                    | 0.036   |
| Chronic kidney disease            | 5.8%                     | 9.8%                    | 0.02    |
| Chronic heart failure             | 2.5%                     | 13.7%                   | <0.001  |
| Peripheral vascular disease       | 3.9%                     | 4.8%                    | 0.476   |
| Chronic lung disease              | 5.3%                     | 10.9%                   | 0.001   |
| Hypertension                      | 66.0%                    | 73.4%                   | 0.006   |
| Diabetes                          | 28.7%                    | 34.9%                   | 0.028   |
| Killip Class                      |                          |                         | <0.001  |
| I                                 | 93.5%                    | 84.5%                   |         |
| II                                | 5.1%                     | 12.5%                   |         |
| III                               | 1.4%                     | 2.1%                    |         |
| IV                                | 0.0%                     | 0.9%                    |         |
| LV systolic function              |                          |                         | <0.001  |
| Normal                            | 80.7%                    | 64.3%                   |         |
| Mild                              | 10.9%                    | 15.7%                   |         |
| Moderate                          | 5.9%                     | 9.3%                    |         |
| Severe                            | 2.5%                     | 10.7%                   |         |
| ECG findings                      |                          |                         |         |
| ST depression                     | 23.7%                    | 26.6%                   | 0.278   |
| ST elevation                      | 9.4%                     | 11.6%                   | 0.265   |
| LBBB                              | 2.5%                     | 5.5%                    | 0.02    |
| Family history of CAD             | 75.8%                    | 71.0%                   | 0.075   |

Data are reported as mean±SD or %. CABG indicates coronary artery bypass graft surgery; CAD, coronary artery disease; CVA, cerebrovascular accident; DAPT, dual antiplatelet therapy; ECG, electrocardiogram; GP IIb/IIIa, glycoprotein IIb/IIIa; GRACE, Global Risk of Acute Coronary Events; LBBB, left bundle-branch block; LV, left ventricular; MI, myocardial infarction; NCDR, National Cardiovascular Data Registry; NSTEMI, non–ST elevation myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.
requiring CABG, the GRACE CABG Risk Scores, were slightly higher for those pretreated with DAPT compared with those who were not (10.0±1.6 versus 9.7±1.8, \( P=0.002 \)), but the risk of bleeding, as assessed with NCDR CathPCI Bleeding Risk Scores, was lower in those pretreated with DAPT (50.6±14.9 versus 55.2±18.3, \( P<0.001 \)).

**Adjusted Association of Patient Factors With DAPT Pretreatment**

Independent predictors of pretreatment with DAPT included higher hemoglobin levels (odds ratio [OR] per 1 g/dL 1.18, 95% CI 1.08–1.29 per 1 g/dL), race other than white or black (OR 0.41, 95% CI 0.21–0.83), and mild (OR 0.55, 95% CI 0.36–0.84), moderate (OR 0.60, 95% CI 0.35–1.03), and severe LV dysfunction (OR 0.3, 95% CI 0.13–0.65). Patients’ bleeding risk (assessed with NCDR CathPCI Bleeding Risk Scores for an increase by 10 points) (OR 0.85, 95% CI 0.74–0.99) was also significantly associated with DAPT pretreatment. The patients’ risk for needing CABG (as assessed with the GRACE CABG Risk Score for 1-point increase in total score [OR 1.09, 95% CI 1.08–1.35]) was not associated with DAPT pretreatment. The main predictors in the regression model are shown in Figure 2. The final model had a c-statistic of 0.83.

**Variability in DAPT Pretreatment Across Centers**

Marked variability in DAPT pretreatment was observed across sites ranging, from 0% to 100% (Figure 3). After adjusting for patient characteristics in a hierarchical model, the MOR was 3.94 (95% CI 2.04–6.09) with \( P<0.0001 \). This suggests an almost 4-fold mean variation in the likelihood that a patient with NSTEMI presenting at 1 random site in the TRIUMPH study would be treated with DAPT before PCI versus another.

**Discussion**

As the United States transitions to value-based healthcare reimbursement, the importance of delivering consistent, guideline-concordant care grows ever more important and insights into the source of treatment variability become a priority. In this multicenter registry of patients with NSTEMI, we found marked variability in the rates of DAPT pretreatment across sites, ranging from 0% to 100%. Importantly, we observed an independent association between a number of
variables suggesting increased risk from DAPT and the avoidance of DAPT pretreatment, such as lower hemoglobin levels, taking anticoagulants on admission, and bleeding risk. However, we found no independent association between patients’ likelihood of needing CABG and the avoidance of DAPT pretreatment. After adjusting for all patient characteristics independently associated with DAPT pretreatment, we still found marked variability in treatment across hospitals. On average, a given patient with NSTEMI presenting at one TRIUMPH site versus another would be almost 4 times more likely to be pretreated with DAPT. This large degree of variation across sites suggests that site-level interventions are needed to improve the consistency of DAPT pretreatment for patients with NSTEMI undergoing PCI across hospitals.

Our work expands on the current understanding of practice patterns surrounding pretreatment with DAPT. We found that the majority of patients with NSTEMI in our study cohort did not receive DAPT pretreatment, which is similar to previous studies.2,3 A retrospective analysis published in 2010, assessing 6253 patients who underwent PCI, showed that 56% of patients with NSTEMI or unstable angina did not receive pretreatment with DAPT.52 Also, in a randomized controlled trial of 9492 patients with high-risk acute coronary syndromes, conducted in 29 countries, Giugliano et al showed that the rate of intended early use of clopidogrel as a part of DAPT was lower in North America than elsewhere (50.8% versus 85.8%).23 The most common reasons cited by previous studies for physicians not pretreating patients with DAPT are the risk of increased bleeding and the likelihood that patients may need to undergo CABG and will be susceptible to prolonged hospital stays.4 In our study, we studied in detail how strongly the risk of bleeding or other clinical factors may be associated with DAPT pretreatment. Our analyses showed that patients taking oral anticoagulants or who had high NCDR CathPCI Bleeding Risk Scores with any degree of LV dysfunction were less likely to receive DAPT pretreatment. On the other hand, patients with a higher hemoglobin level had higher odds of being pretreated. These observations suggest that providers may be rationally considering the risk of bleeding as well as how stable patients are with regard to their cardiac function when deciding whether to pretreat patients with DAPT. Our study further showed that patients who were not black or white were less likely to receive DAPT. A potential reason for this is that despite being underrepresented in major clinical trials, there is evidence to suggest that minority groups, especially Asian patients, are more prone to bleeding complications following PCI, compared with white patients.24 Therefore, providers might be considering this risk of bleeding in these minority patients and be less likely to pretreat them with DAPT. However, further research is needed to evaluate this relationship. More importantly, we found that DAPT pretreatment was not significantly associated with the patients’ GRACE model risk score, leading us to believe that providers may not be considering the risk of CABG as an important factor to give or delay DAPT. The significant variability in rates of pretreatment with DAPT across facilities that was present even after accounting for patient-level factors shows that providers are not using a standardized approach to risk-stratify patients for purposes of administering or delaying DAPT pretreatment.

American Heart Association/American College of Cardiology and European Society of Cardiology guidelines recommend initiating DAPT at the earliest time after presentation to the hospital and before angiography (pretreatment).1,2,4 These recommendations are mainly based on evidence from the Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE)5 and the Clopidogrel for the Reduction of Events During Observation (CREDO) trials,6 which were conducted more than a decade ago and may not represent contemporary practice trends. In these studies, most of the patients had their PCIs postponed for up to several days after pretreatment, whereas current practice often leads to invasive treatment within hours of first medical contact. Also, recent studies suggest that DAPT pretreatment may not necessarily improve cardiovascular outcomes.17,19 A recent meta-analysis showed that 32 383 NSTEMI patients who received pretreatment with aspirin and clopidogrel did not have a significantly lower risk of mortality.19 Another randomized trial (the Comparison of Prasugrel at the Time of PCI or Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction [ACCOAST]) enrolled 4033 NSTEMI patients and found that
pretreatment with prasugrel (a more potent antiplatelet agent than clopidogrel) did not decrease adverse cardiac outcomes but rather was associated with increased bleeding. Therefore, if patient-centered reasons (like risk of bleeding) are the cause of the low DAPT pretreatment, then deviating from guidelines may not necessarily provide poor care, especially in light of new emerging evidence. In contrast, if site-level variability accounts for the use of DAPT before coronary angiography independent of patient-level factors, then it would underscore the importance of quality improvement efforts to improve guideline concordance and improve the consistency of care. Previously proposed models that either predict the likelihood for CABG or estimate the bleeding risk for patients presenting with NSTEMI may not be perfect. However, these prediction models could provide clinicians with evidence-based guidance for the selection of DAPT pretreatment, thereby providing a more standardized approach to treating patients with NSTEMI, potentially reducing practice variations and helping to increase adherence to the guidelines.

Our findings should be considered in the context of several potential limitations. At the time of our study (2005–2008), there was little controversy regarding giving DAPT pretreatment. However, the addition of newer P2Y-12 inhibitors with a more rapid onset of action and conflicting data, such as those from ACCOAST, may suggest that pretreatment is less important now than at the time of this study. Nevertheless, insights separating patient-level from site-level variability are important and whatever practice patterns are eventually adopted would likely require site-level interventions to support the consistency of care across hospitals. In addition, although we attempted to look at a comprehensive list of patient-level factors that were potentially associated with DAPT pretreatment, we could have missed important variables, which could have influenced/confounded our results, but our logistic regression model had a good discrimination with c-statistic of 0.83 providing us with reasonable confidence in the results. Also, glycoprotein IIb/IIIa inhibitors are a form of antiplatelet therapy that can also be administered upstream of angiography and influence DAPT pretreatment, but as we did not have data regarding the exact time of administration of these medications (whether patients received them before or after getting DAPT), we did not include them as a “predictor variable” in our logistic regression analyses. Finally, we only explored practice trends of DAPT pretreatment and did not examine outcomes, as previous large-scale trials have already explored this.

In our multicenter MI registry, less than one-fourth of NSTEMI patients were pretreated with DAPT, and while patient characteristics associated with increased bleeding risk were also associated with less DAPT pretreatment, there remained marked variation across sites even after adjusting for these patient factors. These findings suggest that the use of DAPT before angiography in NSTEMI patients is more influenced by site-level protocols, rather than personalized care to individual patients. Efforts to improve the quality of DAPT pretreatment should focus on site-level interventions, which seem more important than any patient-level considerations in current practice.

Sources of Funding

Funding support for the TRIUMPH Registry was received from the National Heart, Lung, and Blood Institute of the National Institutes of Health (PS0 HL077113). The funding agency had no role in data collection, analysis, interpretation, or the decision to submit the results. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Dr Jang was supported by a grant from research year of Inje University in 2014 (20131465). Dr Shaﬁq and Dr Qintar received support from the National Heart, Lung, and Blood Institute under award T32HL110837.

Disclosures

Dr Spertus reports consultant fees/honoraria from HealthCare, Genentech, Amgen, Janssen, and Novartis. He has received grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health, PCORI, ACCF, Gilead, Lilly, EvaHeart, and Amcyote. He owns the copyright to the Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, and Peripheral Artery Questionnaire and has an equity interest in Health Outcomes Sciences. Dr Cohen reports consultant fees/honoraria from Abbott Vascular, MEDTRONIC, and Merck, Inc. He has received grants from Abbott Vascular, Astra Zeneca, Biomet, Inc, Boston Scientific, Cardiovascular Systems, Inc. (CSI), Daiichi Sanyko, Edwards Life Sciences, Eli Lilly, and MEDTRONIC. Dr Bach reports consultant fees/honoraria from Eli Lilly, Novo Nordisk, Relypsa, Inc, and Wyeth/Pfizer. He has received grants from Bristol-Myers Squibb, Eli Lilly, and Merck/Schering Plough Research Institute.

References

1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Ziemer SJ, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–e228.
2. Don CW, Roe MT, Li S, Fraulo E, Pomerantsev E, Palacios I, Wiviott SD. Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. Am Heart J. 2011;161:689–697.
3. Burke MA, Lee R, Fintel DJ. Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. Am Heart J. 2011;161:832–841.
4. Mahla E, Metzler H, Tantry US, Gurbel PA. Controversies in oral antiplatelet therapy in patients undergoing aorto-coronary bypass surgery. Ann Thorac Surg. 2010;90:1040–1051.

5. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21:2033–2041.

6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N Engl J Med. 1998;338:1488–1497.

7. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrin therapy. N Engl J Med. 1998;339:436–443.

8. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLuca P, DiBattiste P, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887.

9. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg. 2005;79:1210–1216.

10. Brieger D, Ellis M, Gore J, Knodel E, Nussbacher A, Piegsa LS, Allegrone J, Anderson FA, Avezum A. Predicting coronary artery bypass graft surgery in acute coronary syndromes. EuroIntervention. 2007;2:452–458.

11. Poppe T, Singal B, Cowen M, Srikanth A, Goraya TY. Is it possible to safely administer early a loading dose of clopidogrel before coronary angiography to patients who are candidates for percutaneous coronary intervention? Am J Cardiol. 2009;104:1505–1510.

12. Sadanandan S, Cannon CP, Gibson CM, Murphy SA, Di Battiste P, Gibson CM, Braunwald E. A risk score to predict need for coronary artery bypass graft surgery in patients with non-ST-segment elevation acute coronary syndromes. Ann Thorac Surg. 2004;78:2022–2026; discussion 2026-7.

13. Garcia S, Canoniero MJ, Chirinos JA, de Marchena E, Salerno T, Ferreira A. Development of a score to predict the need for coronary artery bypass graft surgery in patients with non-ST-segment elevation acute coronary syndromes. Ann Thorac Surg. 2004;78:2022–2026; discussion 2026-7.

14. Shaﬁq A, Kureshi F, Jang JS, Fedl Inter T, Gosch K, Jones P, Bach B, Cohen D, Spertus J. Predicting the likelihood for coronary artery bypass grafting in non-ST-elevation myocardial infarction patients. Am J Cardiol. 2015;115(10-S).

15. Rao SV, McCoy LA, Spertus JA, Krone R, Singh M, Fitzgerald S, Peterson ED. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding deﬁnition from the National Cardiovascular Data Registry CathPCI Registry. JACC Cardiovasc Interv. 2013;6:897–904.

16. Arnold SV, Chan PS, Jones PG, Decker C, Buchanan DM, Krumholz HM, Ho PM, Spertus JA. Translational research investigating underlying disparities in acute myocardial infarction patients’ health status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes. 2011;4:467–476.

17. Spertus J, Deckar C, Woodman C, House J, Jones P, O’Keefe J, Borkan AM. Effect of inadequate afﬁrming health care on health status after coronary revascularization. Circulation. 2005;111:2572–2578.

18. Rahimi AR, Spertus JA, Reid KJ, Bernheim SM, Krumholz HM. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA. 2007;297:1063–1072.

19. Larsen K, Merlo J. Appropriate assessment of neighborhood effects on individual health: integrating random and ﬁxed effects in multilevel regression. Am J Epidemiol. 2005;161:81–88.

20. Merlo J, Chiax B, Ohlsson H, Beckman A, Johnell K, Hjerpe P, Rastam L, Larsen K. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health. 2006;60:290–297.

21. Raghunathan TE, Solenberger P, Hoewyk JV. IVEware: Imputation and Variance Estimation Software. 2007. Available at: http://www.isr.umich.edu/src/ive/ Accessed May 26, 2016.

22. Dean BB, Yu HT, Bae JP, Fiske S, Meadows E, Xiong Y, Emons MF. Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions. Am J Health Syst Pharm. 2010;67:1430–1437.

23. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van’t Hof A, Berdan LG, Lee KL, Strongy JT, Hildemans S, Velti E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LC. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360:2176–2190.

24. Mak KH, Bhattacharjee D, Shao H, Hankey GJ, Easton JD, Fox KA, Topol EJ. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009;158:655–668.

25. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Casadei B, Hindricks G, Katus HA, Klug MG, Lancellotti P, Montalescot G, Newby LC, Ohman EM, Timmis A, Torp-Pedersen C, Uhrig S, Urban P, Verheugt FW, Yusuf S, Zamorano JL, Zoghbi WA, Zeymer U. ESC guidelines on the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.

26. Steinhubl SR, Berger PB, Mann JT III, Fry ET, Delago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420.

27. Berwick DM. Continuous improvement as an ideal in health care. N Engl J Med. 1989;320:53–56.
Table S1. Comparison of Logistic Regression Models with and without Missing Data

| Variables                                      | Model with Missing Data | Model with Imputed Data |
|------------------------------------------------|-------------------------|-------------------------|
| Age (yrs)                                      | 1.00 (0.92-1.09)        | 1.01 (0.93-1.10)        |
| Male versus female                             | 0.67 (0.40-1.11)        | 0.68 (0.41-1.11)        |
| Race (reference = white)                       |                         |                         |
| Black                                          | 1.02 (0.68-1.52)        | 1.05 (0.71-1.55)        |
| Other                                          | 0.45 (0.22-0.91)        | 0.41 (0.20-0.83)        |
| Angina                                         | 1.12 (0.58-2.16)        | 1.00 (0.53-1.88)        |
| Prior bypass graft surgery                     | 0.79 (0.33-1.88)        | 0.89 (0.39-2.03)        |
| Prior AMI                                      | 0.86 (0.55-1.36)        | 0.86 (0.55-1.32)        |
| Prior PCI                                      | 1.00 (0.62-1.61)        | 1.01 (0.63-1.60)        |
| CVA/TIA                                        | 0.93 (0.50-1.71)        | 0.95 (0.52-1.72)        |
| Chronic kidney disease                         | 1.37 (0.73-2.58)        | 1.44 (0.77-2.6)         |
| Congestive heart failure                       | 0.51 (0.22-1.15)        | 0.51 (0.22-1.14)        |
| Peripheral vascular disease                    | 1.05 (0.51-2.16)        | 0.98 (0.48-1.99)        |
| Chronic lung disease                           | 0.73 (0.40-1.33)        | 0.73 (0.40-1.31)        |
| Hypertension                                   | 1.02 (0.67-1.54)        | 0.94 (0.63-1.40)        |
| Diabetes                                       | 0.91 (0.59-1.39)        | 0.86 (0.57-1.30)        |
| Family history of CAD                          | 1.21 (0.86-1.70)        | 1.18 (0.85-1.64)        |
| *LV Function (reference=normal)*               |                         |                         |
| Mild                                           | 0.59 (0.38-0.90)        | 0.55 (0.36-0.84)        |
| Moderate                                       | 0.59 (0.34-1.05)        | 0.60 (0.34-1.03)        |
| Severe                                         | 0.36 (0.15-0.83)        | 0.29 (0.13-0.65)        |
| *Smoking status (reference=current smoker)*    |                         |                         |
| Former                                         | 1.09 (0.75-1.59)        | 1.08 (0.75-1.56)        |
| Never                                          | 0.98 (0.68-1.42)        | 0.96 (0.67-1.38)        |
| Warfarin                                       | 0.56 (0.24-1.32)        | 0.58 (0.26-1.29)        |
| Hemoglobin                                     | 1.19 (1.09-1.31)        | 1.18 (1.08-1.29)        |
| Platelet count (per 25 units)                  | 0.97 (0.93-1.02)        | 0.98 (0.94-1.03)        |
| *EKG*                                          |                         |                         |
| ST depression                                  | 0.95 (0.67-1.36)        | 0.88 (0.62-1.24)        |
| ST elevation                                   | 0.92 (0.46-1.83)        | 1.06 (0.55-2.06)        |
| NCDR Bleeding Risk Score (per 10 points)       | 0.85 (0.73-0.99)        | 0.85 (0.73-0.98)        |
| GRACE CABG Score (per 1 point increase)        | 1.04 (0.83-1.30)        | 1.08 (0.87-1.34)        |

AMI, acute myocardial infarction; CAD, coronary artery disease; CVA, cerebrovascular disease; LV, left ventricular; NCDR, National Cardiovascular Data Registry; PCI, percutaneous coronary intervention;
Variation in Practice Regarding Pretreatment With Dual Antiplatelet Therapy for Patients With Non–ST Elevation Myocardial Infarction
Ali Shafiq, Javier Valle, Jae-Sik Jang, Mohammed Qintar, Kensey Gosch, David J. Cohen, Mandeep Singh, Richard Bach and John A. Spertus

J Am Heart Assoc. 2016;5:e003576; originally published June 10, 2016; doi: 10.1161/JAHA.116.003576
The Journal of the American Heart Association is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/5/6/e003576